Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSCG | ISIN: US00510M1045 | Ticker-Symbol: 3ZO
Stuttgart
05.11.24
08:06 Uhr
1,680 Euro
-0,004
-0,24 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACURX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ACURX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6581,74212:40
1,6581,74212:28

Aktuelle News zur ACURX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoNew to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR's "Hack of the Week"229The episode, airing at 9:30 PM PST, will include insights from The Sustainable Green Team with CEO Tony Raynor and Jimmy Houston.NEW YORK, NY / ACCESSWIRE / October 31, 2024 / New to The Street, a premier...
► Artikel lesen
28.10.New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical , Acurx Pharmaceuticals , and LightPath Technologies184Also appearing on the show are, Sustainable Green Team (OTCQX:SGTM), Andie Monet with David Fagen, and SEKUR (OTCQX:SWISF)NEW YORK, NY / ACCESSWIRE / October 28, 2024 / New to The Street on Fox Business...
► Artikel lesen
21.10.Acurx reports positive Phase 2 results for CDI treatment ibezapolstat1
21.10.Acurx Pharmaceuticals, Inc.: Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference54The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C. difficile Infection (CDI) Ibezapolstat treatment...
► Artikel lesen
14.10.New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support283The new series features continued broadcast television interviews, earned media placements, and a comprehensive outdoor advertising campaign.NEW YORK, NY / ACCESSWIRE / October 14, 2024 / New to The...
► Artikel lesen
26.09.Acurx berichtet über positive Mikrobiomeffekte und Anthrax-Aktivität von Ibezapolstat1
26.09.Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity1
26.09.Acurx Pharmaceuticals, Inc.: Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues47New analyses extend data on beneficial effects of ibezapolstat on the gut microbiome Confirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic concentrations Selected...
► Artikel lesen
24.09.Acurx readies ibezapolstat for Phase 3 CDI trials2
24.09.Acurx bereitet Ibezapolstat für Phase-3-Studien bei CDI vor1
10.08.Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript2
09.08.Earnings call: Acurx Pharmaceuticals outlines funding strategies for Phase 3 trials2
09.08.Acurx Pharmaceuticals, Inc. - 8-K, Current Report1
09.08.Acurx Pharmaceuticals GAAP EPS of -$0.26 misses by $0.041
09.08.Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update162STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
► Artikel lesen
08.08.Acurx Pharmaceuticals, Inc. - 10-Q, Quarterly Report-
15.05.Earnings call: Acurx Pharmaceuticals outlines ibezapolstat progress1
15.05.Acurx Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary1
15.05.Acurx Pharmaceuticals, Inc. - 8-K, Current Report1
15.05.Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update108STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class...
► Artikel lesen
Seite:  Weiter >>
28 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1